| Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. | |
| | |
MedLine Citation:
|
PMID: 18448752 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To systematically review evidence of the treatment benefits of selective serotonin reuptake inhibitors (SSRIs) for symptoms related to severe premenstrual syndrome (PMS) and premenstrual dysphoric disorder. DATA SOURCES: We conducted electronic database searches of MEDLINE, Web of Science, Cochrane Library, Embase, PsycINFO, and Cinahl through March 2007, and hand-searched reference lists and pertinent journals. METHODS OF STUDY SELECTION: Studies included in the review were double-blind, randomized, controlled trials comparing an SSRI with placebo that reported a change in a validated score of premenstrual symptomatology. Studies had to report follow-up for any duration longer than one menstrual cycle among premenopausal women who met clinical diagnostic criteria for PMS or premenstrual dysphoric disorder. From 2,132 citations identified, we pooled results from 29 studies (in 19 citations) using random-effects meta-analyses and present results as odds ratios (ORs). TABULATION, INTEGRATION, AND RESULTS: Our meta- analysis, which included 2,964 women, demonstrates that SSRIs are effective for treating PMS and premenstrual dysphoric disorder (OR 0.40, 95% confidence interval [CI] 0.31-0.51). Intermittent dosing regimens were found to be less effective (OR 0.55, 95% CI 0.45-0.68) than continuous dosing regimens (OR 0.28, 95% CI 0.18-0.42). No SSRI was demonstrably better than another. The choice of outcome measurement instrument was associated with effect size estimates. The overall effect size is smaller than reported previously. CONCLUSION: Selective serotonin reuptake inhibitors were found to be effective in treating premenstrual symptoms, with continuous dosing regimens favored for effectiveness. |
| | |
Authors:
|
Nirav R Shah; J B Jones; Jaclyn Aperi; Rachel Shemtov; Anita Karne; Jeff Borenstein |
Publication Detail:
|
Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 111 ISSN: 0029-7844 ISO Abbreviation: Obstet Gynecol Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-05-01 Completed Date: 2008-06-12 Revised Date: 2010-08-18 |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 1175-82 Citation Subset: AIM; IM |
Affiliation:
|
Division of General Internal Medicine, New York University School of Medicine, New York, New York, USA. nirav.shah@med.nyu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Citalopram / therapeutic use Female Fluoxetine / therapeutic use Fluvoxamine / therapeutic use Humans Odds Ratio Paroxetine / therapeutic use Premenstrual Syndrome / drug therapy* Serotonin Uptake Inhibitors / therapeutic use* Sertraline / therapeutic use Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
F32 HL074478-02/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Serotonin Uptake Inhibitors; 54739-18-3/Fluvoxamine; 54910-89-3/Fluoxetine; 59729-33-8/Citalopram; 61869-08-7/Paroxetine; 79617-96-2/Sertraline |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship of time since childbirth and other pregnancy factors to premenopausal breast cancer pro...
Next Document: Preoperative evaluation of the gynecologic patient: considerations for improved outcomes.